98%
921
2 minutes
20
Rheumatoid arthritis (RA) is an autoimmune condition characterized by widespread and persistent inflammation. In this study, we sought to investigate the association between the systemic inflammation response index (SIRI) and the likelihood of RA occurrence among individuals in the United States. This study conducted a retrospective analysis using data collected from the National Health and Nutrition Examination Survey from 1999 to 2020. The relationship between SIRI and the likelihood of rheumatoid arthritis was evaluated through multivariable logistic regression models. To investigate potential nonlinear associations, restricted cubic spline functions were applied. Additionally, subgroup analyses were carried out to assess whether demographic and clinical variables modified these associations. Fourteen thousand, three hundred seventy-four participants were included in this study, among whom 1412 individuals (9.8%) were diagnosed with RA. SIRI = (neutrophil count × monocyte count)/lymphocyte count. We found a nonlinear L-shaped relationship between SIRI and the risk of RA, with the range of low-risk SIRI levels being 1.1 to 2.29. This finding suggests that individuals falling outside the range have an increased risk of developing RA. The overall linear trend indicated that each unit increase in SIRI corresponded to a 5% increased risk of RA occurrence (95% confidence interval: 1.01-1.10), and this association was more pronounced in males. In U.S. adults, an L-shaped nonlinear relationship exists between the inflammatory biomarker SIRI and the risk of developing RA. These findings provide new insights for the early identification of RA disease onset.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MD.0000000000044269 | DOI Listing |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419437 | PMC |
JAMA Netw Open
September 2025
Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla.
Importance: Janus kinase (JAK) inhibitors are highly effective medications for several immune-mediated inflammatory diseases (IMIDs). However, safety concerns have led to regulatory restrictions.
Objective: To compare the risk of adverse events with JAK inhibitors vs tumor necrosis factor (TNF) antagonists in patients with IMIDs in head-to-head comparative effectiveness studies.
Curr Rheumatol Rep
September 2025
Medical School of Hubei Enshi College, Enshi, 445000, China.
Inflammopharmacology
September 2025
Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, 140401, India.
The NOD‑like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a key molecular complex that amplifies inflammatory cascades by maturing interleukin‑1 beta (IL-1β) and interleukin‑18 (IL-18) and inducing pyroptosis. It serves as a major driver and co-driver of numerous diseases associated with chronic inflammation. Dysregulated NLRP3 activation contributes to the progression of disorders such as rheumatoid arthritis, inflammatory bowel disease, neurodegenerative diseases and atherosclerosis.
View Article and Find Full Text PDFActa Derm Venereol
September 2025
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Medicine A, Assuta Ashdod University Hospital, Ashdod, Israel.
Rheumatology (Oxford)
September 2025
Department of Molecular Targeted Therapeutics, University of Occupational and Environmental Health, Kitakyushu, Japan, Japan.